Analysis of Serum Metabolome in Mice with Gastric Cancer Treated with JPYZXZ Prescription Based on Liquid Chromatography-Mass spectrometry

OBJECTIVE   To observe the changes of serum metabolites in mice with gastric cancer before and after giving JPYZXZ prescription by metabolomics, and to find the characteristic molecules related to the efficacy of the prescription in the treatment of gastric cancer, and to explore the role of JPYZXZ prescription in regulating the local microenvironment and endogenous mechanism of gastric cancer.METHODS   A subcutaneous transplantation tumor model of human gastric cancer in nude mice was established and randomly divided into a model group, a low-dose group of JPYZXZ prescription, and a high-dose group of JPYZXZ prescription. The serum samples of each group were detected by ultra performance liquid chromatography-mass spectrometry (UPLC-Q-TOF/MS), the differential metabolites were screened by principal components analysis (PCA) and orthogonal partial least squares- discriminant analysis (OPLS-DA), and MetaboAnalyst was used to analyze the relevant metabolic pathways.RESULTS   The mean tumor weight of mice in the high and low dose groups was significantly smaller than that of the model group (P < 0.05). The results of metabolomics showed that the serum samples of the model group, the low-dose group, and the high-dose group could be well distinguished, and the levels of endogenous metabolites in the mice with gastric cancer were varying degrees of callbacks after the administration of JPYZXZ prescription, and 5 different metabolites and 4 related metabolic pathways were identified preliminarily.CONCLUSION   JPYZXZ prescription can significantly inhibit the growth of tumors in mice, and its mechanism of action may be related to the increase of arachidonic acid level and the activation of α-linolenic acid and linoleic acid metabolism and arachidonic acid metabolic pathway.